RH price target raised to $325 from $300 at JPMorgan 07:33 RH JPMorgan analyst Christopher Horvers raised the firm's price target on RH to $325 from $300 and keeps an Overweight rating on the shares. The analyst updated his model post the Q2 results and says second half of 2022 estimates "look beatable."
Dice Therapeutics initiated with an Overweight at Cantor Fitzgerald 07:33 DICE--
Dice Therapeutics initiated with an Overweight at Cantor Fitzgerald 06:56 DICE Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Dice Therapeutics with an Overweight rating and $36 price target.
Vir Biotechnology initiated with an Outperform at SVB Securities 07:17 VIR
DraftKings price target raised to $34 from $31 at Guggenheim 07:09 DKNG
Dice Therapeutics initiated with an Overweight at Cantor Fitzgerald 07:33 DICE--
Dice Therapeutics initiated with an Overweight at Cantor Fitzgerald 06:56 DICE Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Dice Therapeutics with an Overweight rating and $36 price target.
Vir Biotechnology initiated with an Outperform at SVB Securities 07:17 VIR
DraftKings price target raised to $34 from $31 at Guggenheim 07:09 DKNG
